key: cord-0016143-odf75a7b
authors: Alonso, Sergi; Tan, Monique; Wang, Changqiong; Kent, Seamus; Cobiac, Linda; MacGregor, Graham A.; He, Feng J.; Mihaylova, Borislava
title: Impact of the 2003 to 2018 Population Salt Intake Reduction Program in England: A Modeling Study
date: 2021-03-01
journal: Hypertension
DOI: 10.1161/hypertensionaha.120.16649
sha: a071b5c1d121e6a4c590a9ff93fbc8f073f76172
doc_id: 16143
cord_uid: odf75a7b

The United Kingdom was among the first countries to introduce a salt reduction program in 2003 to reduce cardiovascular disease (CVD) incidence risk. Despite its initial success, the program has stalled recently and is yet to achieve national and international targets. We used age- and sex-stratified salt intake of 19 to 64 years old participants in the National Diet and Nutrition Surveys 2000 to 2018 and a multistate life table model to assess the effects of the voluntary dietary salt reduction program on premature CVD, quality-adjusted survival, and health care and social care costs in England. The program reduced population-level salt intake from 9.38 grams/day per adult (SE, 0.16) in 2000 to 8.38 grams/day per adult (SE, 0.17) in 2018. Compared with a scenario of persistent 2000 levels, assuming that the population-level salt intake is maintained at 2018 values, by 2050, the program is projected to avoid 83 140 (95% CI, 73 710–84 520) premature ischemic heart disease (IHD) cases and 110 730 (95% CI, 98 390–112 260) premature strokes, generating 542 850 (95% CI, 529 020–556 850) extra quality-adjusted life-years and £1640 million (95% CI, £1570–£1660) health care cost savings for the adult population of England. We also projected the gains of achieving the World Health Organization target of 5 grams/day per adult by 2030, which by 2050 would avert further 87 870 (95% CI, 82 050–88 470) premature IHD cases, 126 010 (95% CI, 118 600–126 460) premature strokes and achieve £1260 million (95% CI, £1180–£1260) extra health care savings compared with maintaining 2018 levels. Strengthening the salt reduction program to achieve further reductions in population salt intake and CVD burden should be a high priority.

xcess salt intake is strongly linked with raised blood pressure (BP) and thereby increased risks of cardiovascular disease (CVD), as well as with kidney disease, gastric cancer, and osteoporosis, [1] [2] [3] [4] [5] and is recognized as a global health challenge. 6 Raised BP (>115/75 mm Hg) is responsible for half of the burden of ischemic heart disease (IHD) and >60% of stroke burden. 7 Consequently, the World Health Organization (WHO) and national governments have issued recommendations to reduce population-level salt intake. 6, 8 Different strategies have been implemented to achieve such reductions, most of them involving industry engagement toward voluntary salt reformulation in processed food. 9 Partial success of such strategies has been observed in high-income countries, where about 80% of consumed salt comes from processed foods, 10 including the United Kingdom where it represents up to 86% of all salt intake. 11 Nevertheless, no country has yet achieved salt intake reductions to recommended levels.

Since 1996, the nongovernmental organization, Consensus Action on Salt and Health, have continuously raised awareness about the health benefits of reducing salt intake in the United Kingdom through providing scientific evidence and advocating political action. 12 Such efforts contributed to a voluntary agreement between the United Kingdom government and the food industry. In 2003 to 2010, the Food Standards Agency, in collaboration with the food industry, established salt reduction targets in several food categories under a voluntary scheme, 13 which also involved product labeling, public awareness campaigns, and monitoring of targets' achievement. Reductions in the added salt in processed food were implemented gradually following a stepwise process. 14 Consequently, the average population-level salt intake was reduced by 15% in the period 2000 to 2011, [15] [16] [17] with the decline attributed to food companies reformulating processed products rather than consumers switching to a lower salt diet. 13 The program's success was based on the fact that gradual marginal reductions are undetected by human taste receptors, 18 thus, not affecting consumers' preferences or industry sales.

After several years of sustained salt intake reductions aimed at limiting the burden of excess salt by encouraging companies to reformulate recipes, in 2013, the National Institute for Health and Clinical Excellence recommended a maximum salt intake of 6 grams/day per adult by 2015 and 3 grams/day per adult by 2025. 19 From 2011 to 2017, the salt reduction program continued under the Department of Health as part of the Public Health Responsibility Deal. It first aimed to meet the 2012 targets for reducing salt added into 85 food categories, such as bread, cheese, cereals, or soups; but it lacked the political commitment to achieve further reductions necessary to progress toward the recommended levels. 15 Few of the proposed actions were implemented under the Responsibility Deal and, thus, the program failed to achieve the salt intake targeted: in 2014, the average population-level salt intake among adults remained at about 8 grams/day. 20 By 2018, however, an increase in salt intake was reported in adult women while no progress was reported in adult men. 21 The present study evaluates the long-term effects of the 2003 to 2018 salt intake reduction program in England using a model to project its effects on premature CVD, individuals' healthy survival, and health care and social care costs. Moreover, it estimates the potential effects of further salt intake reductions by 2030. Figure 1 ). All data used in this study are publicly available.

The terms salt and sodium are often used interchangeably. However, on a weight basis, salt comprises 40% sodium and 60% chloride. Salt is the major source of sodium in the diet (≈90%). One gram of sodium=2.5 g of salt. Sodium is the term used in most scientific journals and in nutritional labels in the United States and Canada, and salt is used in Europe and other countries. We used the term salt throughout the article as it reports analysis for England. 4 Nonstandard Abbreviations and Acronyms 

We used publicly available data on salt intake from the National Diet and Nutrition Surveys in adults 19 to 64 year of age in England 21 that assessed salt intake by 24-hour urinary sodium excretion for a representative population sample in years 2000/2001, 2006, 2008, 2011, 2014, and 2018 . The data from complete urinary sodium samples (ie, para-amino benzoic acid ≥70%), stratified by sex and age (19-34, 35-49, ≥50) and adjusted using age-and sex-specific survey weights were used to estimate dietary salt intake (grams/day).

The costs of the salt reduction program were based on estimates by Collins et al, 22 22 and progressive salt reformulations were assumed not to impact on industry sales as consumers progressively adjust to lower-salt diets. 17 UK government costs included the cost of a media campaign conducted between 2009 and 2012 (£41.62 million), as well as the cost of monitoring salt intake in the general population and monitoring food industry activities to guarantee manufacturers are labeling and effectively reducing the salt content of food products (£2.15 million per year each). 22 Annual monitoring costs were assumed over the lifespan of the program, but future media campaigns were discontinued because of their limited effectiveness: public awareness of the salt-related harmful effects temporarily increased during the campaigns but diminished quickly again after the first campaign year. 14 We present program costs for the total population of England.

PRIMEtime-CE is a multistate life table model, which links sociodemographic and behavioral risk factors to noncommunicable diseases' morbidity and mortality and health and social care costs. [23] [24] [25] [26] [27] [28] [29] Figure 2 summarizes the conceptual framework in our study.

We used official statistics on age and sex stratified population distribution and all-cause mortality in England in the year 2000. 30, 31 In mid-2000, the population of England was 49.2 million, 51% of which were female, and 62% were aged above 30 years ( Figure S1 in the Data Supplement). All-cause mortality rates were calculated using deaths registered by age and sex divided by corresponding population estimates ( Figure S2 ). Population was annually adjusted in subsequent years using the age-and sex-specific rates of population increase during 2000 to 2015.

We used an open cohort design to account for all adults over time.

The effects of a reduction in population-level salt intake are propagated in the model through the reduction in BP. 32 The effect of salt intake on BP is based on a meta-analysis by He et al, 32 which estimated that a reduction in salt intake of 6 grams/ day was associated with a decrease of 5.8 mm Hg (95% CI, 2.50-9.20) in systolic BP. Salt intake changes in the model are implemented by sex and age and account for the positive association between higher dietary salt intake and BP: for a given reduction in salt intake, the fall in systolic BP is larger in older compared with younger individuals. 33 Reductions in systolic BP are associated with reductions in risk of CVD, including IHD and stroke. 34 During each year in the model, IHD and stroke prevalence and incidence were computed using population impact fractions, which accounted for the proportion by which disease incidence and mortality in the population were reduced given changes in BP because of the salt reduction program. Table S1 summarizes the parameters, probability distributions, and respective data sources used in the model; as well as the data sources informing the epidemiological estimates used in PRIMEtime-CE.

Quality-adjusted life-years (QALYs) were obtained by combining life years and EQ-5D utilities, associated with included diseases, 35 stratified by age and sex. During each year, the extra years and QALYs, and health care and social care cost savings due to reductions in IHD and strokes associated with the salt reductions achieved, were estimated (Methods in the Data Supplement).

We estimated the effects of the salt reduction program for the adult population in England, aggregated in 5-year bands, over the periods 2000 to 2018 and 2019 to 2050. For both study periods, age-and sex-specific CVD morbidity and mortality were simulated annually according to the risk associated with salt intake. Starting at 2000 levels, population salt intake was assumed to change according to the population-level salt intake observed in England from 2000 to 2018 and to remain at 2018 values for the remaining time horizon. Due to lack of data, individuals older than 64 years of age were assumed to have daily salt intake corresponding to the 50-to 64-year-old age and sex category. We estimated the total premature CVD morbidity and mortality cases, life-years, and QALYs, and health care and social care costs associated with 2000 to 2018 salt intake values, and compared them with those obtained should the salt intake levels remained at 2000 levels (baseline; Figure 1 ). Health gains associated with the salt reduction program were expressed as: premature (ie, before 75 years of age) IHD and stroke cases avoided, and life years and QALYs gained. We considered IHD and stroke cases occurring to individuals dependent on BP reductions and adjusted for decreasing trends in prevalence of CVD according to age and sex. 36 We present nondiscounted CVD cases, life years and QALYs, as well as discounted at 1.5% per annum QALYs gained with the salt reduction program. 37 Health care and social care costs were presented in 2014 UK£ values and discounted at an annual rate of 1.5%. 37 Health care savings were calculated for the period 2000 to 2050 as the difference between the cumulative health care costs associated with the salt intake levels before the salt reduction program (year 2000) minus the cumulative health care costs under decreasing population salt intake in 2000 to 2018. For the base-case analysis, we further calculated the incremental costs to the UK government as the government costs associated with monitoring and administering the salt reduction program minus the cost savings due to reducing health care and/ or social care utilization.

We used PRIMEtime-CE to evaluate 2 additional scenarios with further population-level salt intake reductions after 2018. Between 2019 and 2030, we assumed a linear reduction in the average population-level salt intake (1) equivalent to the annual reduction rate of 1.37% observed over the period 2000 to 2014 (scenario A) or (2) of 3.36% to achieve WHO recommendation of 5 grams/day per adult (scenario B; Figure 1 ). We assumed that thereafter, salt intake was maintained at 2030 levels until 2050. For each scenario, we estimated the health outcomes and health care and social care costs associated with reduced salt intake and expressed the outcomes as the additional premature morbidity and mortality cases averted, lifeyears gained, QALYs gained, as well as the additional health care and social care savings compared with the base-case analysis (maintained salt intake at 2018 levels).

We undertook a probabilistic sensitivity analysis to account for the uncertainty in model parameters using 1000 random draws from their probability distributions (Table S1 ) to estimate the SEs and 95% CIs.

Sensitivity analyses evaluated the impact of model parameters on key results. First, we projected the long-term benefits if the program had not stalled in 2014 to 2018 by assuming continued decrease in salt intake from 2014 to 2030 at the 2000 to 2014 annual rate with achieved reduction by 2030 maintained until 2050. Second, we evaluated the effect of assuming the government salt reduction program was responsible for only half of the observed 2000 to 2018 salt intake decrease. Third, we assessed the impact of using a higher effect of a decrease in salt intake on BP, as estimated from observational data under a more prolonged period of lower salt intake (compared with randomized trials), in which a decrease in salt intake of 1.4 grams/day, as measured by 24-hour urine sodium excretion in a random population sample, was associated with a fall in systolic BP of 2.7 mm Hg. 1 Finally, we used a higher suggested estimate for 2014 population-level salt intake. 38 (Table S2) was somewhat larger in younger adults with >25% reduction in individuals 35 years of age or younger. However, the salt intake trend then stalled and by 2018, men had increased their intake to 9.19 grams/day (0.29) and women to 7.58 grams/day (0.23). Table 1 reports the estimated impact of the achieved reduction in population-level salt intake on CVD burden and health care and social care cost. The model estimated that 27 630 (95% CI, 26 580-27 650) premature IHD and 39 250 (95% CI, 38 500-40 050) premature stroke cases were avoided during the period 2000 to 2018. These health gains translated into 33 660 (95% CI, 31 840-33 750) QALYs gained for the adult population in England. In that period, the overall costs of the salt reduction program reached £103 million (95% CI, £103-£104), whereas the reduced CVD morbidity resulted in health care savings of £310 million (95% CI, £295-£311). Overall, the salt reduction program was cost-saving, estimated to save £860 million (95% CI, £830-£870) in health care and social care costs.

The model estimated that by 2050, even in the absence of further salt intake reductions ( 

The extra benefits with further salt intake reductions in the population of England on CVD morbidity and the health care and social care savings are shown in Table 2. Reducing the population-level salt intake during 2018 to 2030 at the same annual rate observed in 2000 to 2014 was estimated to achieve average salt intake levels of 6.77 grams/day per adult by 2030. Such a reduction was estimated to result in 37 870 (95% CI, 36 310-38 550) further premature IHD cases and 56 310 (95% CI, 54 480-57 890) further premature stroke cases avoided by 2050, representing a 45% and 50% increase respectively of base-case results. Such health gains had additional health care and social care savings of £2560 million (95% CI, £2510-£2620). Achieving larger population salt intake reductions, as recommended by WHO, by 2030 implied an average salt intake reduction of 3.38 grams/day per adult, which led to 87 870 (95% CI, 82 050-88 470) fewer premature IHD cases and 126 010 (95% CI, 118 600-126 460) fewer premature stroke cases by 2050 compared with the health gains in the base-case analysis. This reduction in disease burden led to 343 260 (95% CI, 334 810-352 430) further QALYs gained and additional cost savings of £5330 million (95% CI, £5120-£5380). The program remained a cost-saving policy strategy.

We investigated the impact of specific model assumptions on results. First, we estimated the impact if the salt intake reduction trend from 2000 to 2014 had continued until 2030 (Table S3) . Under this scenario, the estimated premature CVD cases avoided doubled by 2050, with an additional 91 000 premature IHD cases and 143 700 premature stroke cases avoided, while the population quality of life in England increased by further 463 300 QALYs, compared with the base-case analysis. While health gains and governmental savings decreased when we attributed only 50% of salt intake reductions to the salt reduction program (Table S4) , even under this assumption, the program averted 29 300 premature IHD cases and 38 400 premature stroke cases over 2000 to 2050, with £2500 million government cost savings. Conversely, assuming a higher effect of salt intake reduction on BP doubled the premature CVD cases averted (Table S5) with 154 100 premature IHD cases and 205 500 premature stroke cases averted in the period 2000 to 2050 (base-case); and further 312 400 premature IHD cases and 431 200 premature stroke cases potentially averted if the WHO salt intake recommendation was achieved. Finally, adopting the adjusted 2014 salt intake estimates resulted in about 10% less health gains compared with the basecase with the program remaining cost-saving (Table S6) .

The 2003 to 2018 population salt reduction program put in place in England has been remarkably successful in reducing population-level salt intake. We report that, according to our model, this reduction projects 193 870 fewer premature CVD cases and 542 850 extra QALYs *Premature cases are cases among adults up to 75 y of age. †Discounted at 1.5% per annum. ‡Government cost savings calculated as the difference between the total health care and social care savings because of averted CVD minus the government costs of monitoring and administering the salt reduction program.

among the adult population in England by 2050. More importantly, further strengthening and scaling up of the salt reduction program, to achieve the WHO recommendation of 5 grams/day per adult by 2030, could bring further large reductions in CVD burden with 213 880 further premature CVD cases avoided by 2050. These health gains could bring substantial accumulated savings to the UK government of £5330 million by 2050 due to reductions in population need for health care and social care.

Our results underscore the value of investing in public health interventions to reduce the burden of noncommunicable diseases, with substantial savings to the UK government. 39 The food industry in the UK is still producing high-salt products in spite of strong evidence that it is technologically feasible and commercially viable to produce lower-salt products, and there is ample room for incremental reductions in their salt content to achieve further population salt reductions in the United Kingdom. 15 The salt reduction program in England was highly successful until 2011 because of the government pressure on industry to reduce salt content, resulting in a decline in the average population-level salt intake of 14% (Table  S2; 8.3% reduction 2006-2011). A recent study reported 5.1% reduction in the salt content of the UK grocery basket of a nationally representative sample of households from 2005 to 2011. 13 These estimated reductions are consistent with the reduction reported by He et al, in high-salt products in supermarkets (from 3.3 to 1.8 g of salt per serving of product), which identified bread as the single largest contribution to salt to the UK diet: 18% of total salt intake. 14 The salt reductions were also driven mainly by product reformulation, as opposed to net product introduction and changes in consumer preferences. 14 The observed decline in program effectiveness after 2011 21 was attributed to reduction in the government pressure on industry. 15 To get back on track, the program will benefit from (1) a strict enforcement of salt reduction targets, for example, through legislation or financial penalties for food companies failing to comply; (2) setting more stringent salt targets; and (3) extending salt targets to the out-of-home sector, which remain lenient and lack the proper monitoring mechanisms.

Several studies have previously indicated that salt reduction strategies have been effective and cost-effective in the United Kingdom, 22, [40] [41] [42] and worldwide. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Our study adds further important evidence to the literature as it also includes the latest 2018 data on sodium excretion obtained from 24-hour urinary samples, that is, the most accurate way to assess salt intake, to estimate the health gains associated with reducing salt intake. Furthermore, we also project the reduction in CVD burden with further strengthening of salt reduction strategies to achieve the WHO recommendations on salt intake.

Despite the high-quality data on population-level salt intake and disease burden used, our study has some limitations. First, the sample size for 24-hour urine collections was small, particularly after stratifying by age and sex. Second, our model does not capture the effect of salt intake on the burden of gastric cancer, renal disease, and osteoporosis, 2,5,12 and, therefore, likely underestimates the health benefits of the program. Moreover, the effect of salt reduction policies in children 54 were also not included because of lack of salt intake data in children. Finally, the long study period may present a further limitation due to the uncertainty in model parameters, assumptions on continuity of the salt reduction program, and evolution of CVD and salt intake trends. In particular, salt intake trajectories from 2019 onward are a main source of uncertainty, especially given the salt intake increase observed after 2014. However, the main objective of the current study was to highlight the long-term population health benefits should the government strengthen and enhance the UK salt reduction program.

The 2003 to 2018 salt reduction program in England achieved an overall salt intake reduction of 1 gram/day in the adult population from 9.38 grams/day per adult in 2000 to 8.38 grams/day per adult in 2018. We modeled the long-term effects of this reduction and demonstrated that the program led to reduced cardiovascular burden and improved quality-adjusted life expectancy of the adult population, as well as yielding large savings in health care and social care. However, reductions in salt intake achieved by 2014 are already being lost. Reversing this and achieving the WHO recommended salt intake of 5 grams/day per adult requires continuous efforts in strengthening the implementation and monitoring of the program. Such efforts are shown likely to be well compensated by further reductions in cardiovascular disease burden.

Received November 5, 2020; accepted January 18, 2021. 

There were no external sources of funding for this study. 

Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality

Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review

Dietary intake, blood pressure and osteoporosis

Guideline: Sodium Intake for Adults and Children

Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors

The European Commission's Science and Knowledge Service. Dietary Salt/ Sodium. Brussels

Salt reduction initiatives around the world -a systematic review of progress towards the global target

The dominance of salt in manufactured food in the sodium intake of affluent societies

WASH-world action on salt and health

The importance of product reformulation versus consumer choice in improving diet quality

Salt reduction in the United Kingdom: a successful experiment in public health

Food and the responsibility deal: how the salt reduction strategy was derailed

Assessment of Dietary Sodium Levels among Adults (Aged 19-64) in England

Reducing the population's sodium intake: the UK Food Standards Agency's salt reduction programme

A one-quarter reduction in the salt content of bread can be made without detection

National Institute for Health and Care Excellence. Cardiovascular Disease Prevention. Manchester

PHE data on salt consumption levels

National Diet and Nutrition Survey: Assessment of Salt Intake from Urinary Sodium in Adults (Aged 19 to 64 Years) in England

An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study

PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity

The preventable risk integrated model and its use to estimate the health impact of public health policy scenarios

Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling

A generic model for the assessment of disease epidemiology: the computational basis of DisMod II

The eatwell guide: modelling the health implications of incorporating new sugar and fibre guidelines

/14 CCG Programme Budgetting Benchmarking Tool

Technical Guide to Allocation Formulae and Pace of Change for 2016-17 to 2020-21 Revenue Allocations to Clinical Commissioning Groups and Commissioning Areas

Office for National Statistics

Effect of longer term modest salt reduction on blood pressure: cochrane systematic review and meta-analysis of randomised trials

Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials

Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies

Catalogue of EQ-5D scores for the United Kingdom

Central Government Guidance on Appraisal and Evaluation. The National Archives

National Diet and Nutrition Survey: Assessment of Dietary Sodium. Adults (19 to 64 Years) in England

World Health Organisation. Regional office for Europe. The Case for Investing in Public Health

Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study

Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis

Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower SBP in the England population

Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations

Modeling health gains and cost savings for ten dietary salt reduction targets

Cost-effectiveness of salt reduction to prevent hypertension and CVD: a systematic review

Cost and health consequences of reducing the population intake of salt

Potential societal savings from reduced sodium consumption in the U.S. adult population

The health gains and cost savings of dietary salt reduction interventions, with equity and age distributional aspects

Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies

Cost-effectiveness of interventions to reduce dietary salt intake

Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use

Projected effect of dietary salt reductions on future cardiovascular disease

MedCHAMPS project team. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries

Sodium intake and blood pressure in children and adolescents: a systematic review and meta-analysis of experimental and observational studies

Effects of scenarios A and B were compared with maintaining 2018 levels until 2050. No additional government costs were included as costs of reformulating specific products were assumed to be absorbed by the food industry. Costs expressed in 2014 UK£. IHD indicates ischemic heart disease; mln, million; and QALY, quality-adjusted life-year.*Premature cases are cases occurring up to 75 y of age. †Discounted at 1.5% per annum.